首页> 外文期刊>Journal of plastic, reconstructive & aesthetic surgery: JPRAS >Donor-derived transplant acceptance-inducing cells in composite tissue allotransplantation
【24h】

Donor-derived transplant acceptance-inducing cells in composite tissue allotransplantation

机译:复合组织同种异体移植中供体来源的移植诱导细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Composite tissue allotransplantation (CTA) is a newly emerging field of transplantation. Immunological research in CTA has been intensified due to the recent clinical success of hand and face transplantation. Establishing immunological tolerance by adoptive transfer of ex vivo cultured tolerance-inducing cell types is of growing interest. Transplant acceptance-inducing cells (TAICs) are a type of deactivated immunoregulatory macrophages. Methods: A total of 36 allogeneic hind limb transplantations in the rat were performed in six groups. Group A (Lewis (LW) → Brown-Norway (BN)) received Lewis-donor-derived TAICs locally (i.m.). Group B (LW → BN) received Lewis-donor-derived TAICs systemically (i.v.) and group C (Sprague Dawley (Sp-D) → BN) served as a control group receiving Lewis-donor-derived TAICs systemically (i.v.). Groups D (LW → BN), E (LW → BN), and F (BN → BN) also served as control groups with group D receiving no immunosuppression, group E receiving FK506 and prednisolone and group F receiving no immunosuppression with isograft transplantations (BN → BN). The timing of rejection was assessed by clinical observation and histological findings. Results: Rejection of the allogeneic hind limb occurred on average 7.7 days after transplantation in group A and 7.4 days in group B. Rejection was significantly delayed (Log-rank test, p < 0.01) compared to groups C and D, where rejection of the allogeneic hind limb occurred on average 5.8 days and 5.6 days after transplantation. No rejection was seen in groups E and F. Conclusion: For the first time, TAICs have been applied in a CTA model and demonstrated a significant immunosuppressive effect. Even though the immunomodulatory effect is relatively modest, the results of this study justify subsequent research on TAIC therapy to improve experimental and clinical outcome after CTA.
机译:背景:复合组织同种异体移植(CTA)是一个新兴的移植领域。由于手和脸移植的近期临床成功,CTA的免疫学研究得到了加强。通过过继转移离体培养的诱导耐受的细胞类型建立免疫耐受的兴趣日益增长。移植诱导诱导细胞(TAIC)是一种失活的免疫调节巨噬细胞。方法:六组大鼠共进行了36次同种异体后肢移植。 A组(刘易斯(LW)→布朗-挪威(BN))在当地(i.m.)接受了路易斯-捐助者提供的TAIC。 B组(LW→BN)全身(i.v.)接受Lewis来源的TAICs,而C组(Sprague Dawley(Sp-D)→BN)全身(i.v.)接受对照组,接受Lewis来源的TAICs。 D组(LW→BN),E(LW→BN)和F(BN→BN)也作为对照组,D组未接受免疫抑制,E组接受FK506和泼尼松龙,F组未接受同种异体移植的免疫抑制( BN→BN)。通过临床观察和组织学发现评估排斥反应的时机。结果:同种异体后肢的排斥反应平均发生在A组,分别在移植后7.7天和B组7.4天。与C和D组相比,异体后肢的排斥反应明显延迟(对数秩检验,p <0.01),C组和D组均被拒绝。异体后肢平均发生在移植后5.8天和5.6天。在E和F组中未见排斥反应。结论:首次将TAIC用于CTA模型并显示出显着的免疫抑制作用。尽管免疫调节作用相对较弱,但这项研究的结果证明了随后进行TAIC治疗以改善CTA后的实验和临床结果的合理性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号